GlassScriptPhysician profile
Christopher Adams Cooper
NPI 1306132600
$3,205.16
in general payments reported to CMS, 2019-2025
32 companies · $18.26 in 2025
The $18.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $593 · 2021: $911 · 2022: $1,067 · 2023: $271 · 2024: $13.28 · 2025: $18.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $614.82 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $496.67 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $353.97 | 2019-2022 | |
| Lilly USA, LLC | $278.22 | 2020-2023 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $193.72 | 2019-2023 | Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.10 | 2019-2024 | Airsupra |
| Pfizer INC. | $105.64 | 2020-2023 | |
| Amgen INC. | $90.75 | 2020-2022 | |
| Abbott Laboratories | $89.19 | 2022-2023 | Freestyle Libre 3 |
| Organon LLC | $63.88 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $63.62 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $61.35 | 2020 | |
| Antares Pharma, INC. | $57.72 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $41.16 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.97 | 2022-2023 | |
| Nevro Corp. | $31.86 | 2023 | Senza |
| Mylan Specialty L.P. | $31.77 | 2022-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.58 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.18 | 2021 | |
| Currax Pharmaceuticals LLC | $25.40 | 2021 | |
| Allergan, INC. | $25.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.04 | 2019-2020 | |
| Medtronic Minimed, INC. | $24.68 | 2020 | |
| Astellas Pharma US INC | $20.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.85 | 2022 | |
| Eisai INC. | $17.33 | 2021 | |
| Amarin Pharma, INC. | $14.42 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.27 | 2022 | |
| Horizon Therapeutics Plc | $14.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.93 | 2023 | Quviviq |
| Neurelis, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.